EUPRAXIA PHARMACEUTICALS INC.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Eupraxia Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on the development of therapeutic candidates designed to address medical indications with high unmet need. The company utilizes proprietary drug delivery technology to optimize and extend the release profile of existing medications. Its primary product pipeline includes EP-104IAR, which targets joint-related inflammatory conditions such as osteoarthritis, and EP-104GI, which is directed toward gastrointestinal disorders. Rather than selling directly to commercial consumers, the company develops its product candidates for eventual healthcare use and collaborates through licensing agreements and clinical partnerships.
The company operates primarily across North America and Australia through several operating subsidiaries, including entities located in Canada, the United States, and Australia. The company maintains its principal executive offices in Victoria, British Columbia, Canada.
Summary of the business section of Eupraxia Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- EUPRAXIA PHARMACEUTICALS INC.
- Headquarters
- Vancouver, British Columbia, Canada
- Address
- 2198 Yukon Street V5Y 3P1
- Phone
- (250) 590-3968
- Website
- eupraxiapharma.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Vancouver, Canada
Stock & identifiers
- Ticker
- EPRX
- Exchange
- Nasdaq
- IPO date
- Apr 5, 2024
- Shares outstanding
- 60M, Dec 31, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1581178
- CUSIP
- 29842P105
- ISIN
- US29842P1057
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Eupraxia Pharmaceuticals's leadership is listed in its proxy statement (Form DEF 14A).
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 18, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |